GlaxoSmithKline Finds a Rich Vein to Mine With Supercomputers - (Bloomberg via NewsPoints Desk)

  • GlaxoSmithKline is partnering with the US and universities in a project to trace the path of unsuccessful drug candidates in an effort to shorten the time required to identify successful molecules, Bloomberg reported.

  • "The industry has to begin sharing its failure," remarked GlaxoSmithKline senior vice president John Baldoni, adding "we want to go where there has been a lot of failure because that's where the most data are."

  • In the Accelerating Therapeutics for Opportunities in Medicine (ATOM) partnership, which will initially focus on cancer, GlaxoSmithKline will provide data on about 2 million molecules and dedicate 12 employees to the project, while another drugmaker is in talks to join the collaboration.

  • Baldoni noted that cancer and other diseases such as Alzheimer's disease are "rich in data, and also rich in failure," adding "I want to go to patients who aren't being served, patients with no hope."

  • GlaxoSmithKline has separately entered into agreements with Exscientia and Insilico Medicine to collaborate on artificial intelligence.

  • ATOM stemmed from discussions held as part of former US Vice President Joe Biden's Cancer Moonshot initiative.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.